CLSI M100JA
Performance Standards for Antimicrobial Susceptibility Testing Japanese Edition
CLSI M100 is the most trusted and widely used resource for antimicrobial susceptibility testing, providing laboratories with the latest breakpoints, dosage recommendations, and quality control standards. This essential reference supports CLSI M02 (disk diffusion), M07 (dilution for aerobic bacteria), and M11 (dilution for anaerobes), ensuring accurate, standardized testing that clinicians depend on for critical patient care.
This edition includes a major reorganization of dosage recommendations for improved clarity, new breakpoints for sulbactam-durlobactam to guide effective treatment, and the addition of Table 2A-2 for Salmonella and Shigella, improving pathogen-specific testing.
Stay ahead in antimicrobial susceptibility testing with the latest, evidence-based standards. Ensure your laboratory is using the most current breakpoints—download CLSI M100 today.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceCLSI M100-Ed34 replaces the previous edition of the supplement, CLSI M100-Ed33, published in 2023. Major additions, reformatting, and/or table relocation changes are summarized below, followed by additional noteworthy changes detailed by section/table. Changes to content since the previous edition appear in boldface type; however, minor editorial or formatting changes are not listed here, nor highlighted in boldface type. To learn more about the organization of CLSI M100-Ed34, check the “Instructions for Use.”
Major Additions/Revisions:
• Tables 1 and Tables 2 (general): These tables were renumbered so that each Table 1 has a corresponding Table 2.
• Table 1I: A new table for suggested drugs to test and report on Neisseria meningitidis was added.
• Table 1J: A combined table for suggested drugs to test and report on anaerobes was added. Previously, these suggestions were listed in separate gram-negative and gram-positive tables.
• Table 2A-2: A new table with breakpoints specific to Salmonella and Shigella spp. was added. Table 2A-1 no longer addresses these organism groups.
• Tables 2, Tables 3, and former Appendix E: In previous editions of CLSI M100, dosage regimens were listed in Tables 2, 3E-2 (now 3F-2), 3E-3 (now 3F-3), and former Appendix E. – Dosage regimens were removed from all Tables 2 and Tables 3F-2 and 3F-3. – Former Appendix E was reformatted, relocated to follow the Tables 2 containing breakpoints, and renamed “Table 2 Dosages. Antimicrobial Agent Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints” (referred to as “Table 2 Dosages” throughout).
• Tables 3 (general): These tables were renumbered to accommodate the addition of new Table 3D.
• Table 3D: A new table describing a broth disk elution method for aztreonam plus ceftazidime-avibactam was added.
• Table 3F-4: A new table with breakpoints specific to testing Acinetobacter spp. directly from positive blood cultures was added. • Table 3H: Former Tables 3G-1 and 3G-2, which described ancillary methods for testing oxacillin and cefoxitin against staphylococci, were condensed into Table 3H, which describes the oxacillin salt agar test only.
• Appendixes (general): These sections were relabeled to accommodate the relocation of former Appendix E (now Table 2 Dosages).
CLSI M100-Ed34 replaces the previous edition of the supplement, CLSI M100-Ed33, published in 2023. Major additions, reformatting, and/or table relocation changes are summarized below, followed by additional noteworthy changes detailed by section/table. Changes to content since the previous edition appear in boldface type; however, minor editorial or formatting changes are not listed here, nor highlighted in boldface type. To learn more about the organization of CLSI M100-Ed34, check the “Instructions for Use.”
Major Additions/Revisions:
• Tables 1 and Tables 2 (general): These tables were renumbered so that each Table 1 has a corresponding Table 2.
• Table 1I: A new table for suggested drugs to test and report on Neisseria meningitidis was added.
• Table 1J: A combined table for suggested drugs to test and report on anaerobes was added. Previously, these suggestions were listed in separate gram-negative and gram-positive tables.
• Table 2A-2: A new table with breakpoints specific to Salmonella and Shigella spp. was added. Table 2A-1 no longer addresses these organism groups.
• Tables 2, Tables 3, and former Appendix E: In previous editions of CLSI M100, dosage regimens were listed in Tables 2, 3E-2 (now 3F-2), 3E-3 (now 3F-3), and former Appendix E. – Dosage regimens were removed from all Tables 2 and Tables 3F-2 and 3F-3. – Former Appendix E was reformatted, relocated to follow the Tables 2 containing breakpoints, and renamed “Table 2 Dosages. Antimicrobial Agent Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints” (referred to as “Table 2 Dosages” throughout).
• Tables 3 (general): These tables were renumbered to accommodate the addition of new Table 3D.
• Table 3D: A new table describing a broth disk elution method for aztreonam plus ceftazidime-avibactam was added.
• Table 3F-4: A new table with breakpoints specific to testing Acinetobacter spp. directly from positive blood cultures was added. • Table 3H: Former Tables 3G-1 and 3G-2, which described ancillary methods for testing oxacillin and cefoxitin against staphylococci, were condensed into Table 3H, which describes the oxacillin salt agar test only.
• Appendixes (general): These sections were relabeled to accommodate the relocation of former Appendix E (now Table 2 Dosages).